Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Biocept, Inc. (BIOC)

1.05   0.055 (5.52%) 08-07 23:37
Open: 1 Pre. Close: 0.9951
High: 1.07 Low: 0.99
Volume: 136,810 Market Cap: 18(M)
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.07 - 1.08 1.08 - 1.08
Low: 0.98 - 0.98 0.98 - 0.99
Close: 1.04 - 1.05 1.05 - 1.06

Technical analysis

as of: 2022-08-05 4:20:32 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.29     One year: 1.51
Support: Support1: 0.99    Support2: 0.92
Resistance: Resistance1: 1.11    Resistance2: 1.29
Pivot: 1
Moving Average: MA(5): 0.99     MA(20): 1
MA(100): 1.44     MA(250): 2.63
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 49.7     %D(3): 38.7
RSI: RSI(14): 53.1
52-week: High: 4.44  Low: 0.83
Average Vol(K): 3-Month: 107 (K)  10-Days: 66 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BIOC ] has closed below upper band by 23.4%. Bollinger Bands are 59.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Sun, 07 Aug 2022
Biocept (NASDAQ:BIOC) Now Covered by - Defense World

Fri, 05 Aug 2022
Price Alert: Shares of Biocept (BIOC) Trade 7.00% Higher at Midday August 5 - Equities News

Sat, 30 Jul 2022
Biocept (NASDAQ:BIOC) Receives New Coverage from Analysts at - Defense World

Fri, 22 Jul 2022
Biocept (NASDAQ:BIOC) Now Covered by Analysts at - Defense World

Thu, 14 Jul 2022
Biocept (NASDAQ:BIOC) Coverage Initiated by Analysts at - Defense World

Sun, 10 Jul 2022
Cobb Board of Commissioners to hold first public hearing on the millage rate this Tuesday, July 12 - Cobb County Courier

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 17 (M)
Shares Float 17 (M)
% Held by Insiders 0 (%)
% Held by Institutions 12.5 (%)
Shares Short 159 (K)
Shares Short P.Month 244 (K)

Stock Financials

EPS -0.53
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.2
Profit Margin (%) -13
Operating Margin (%) -12.3
Return on Assets (ttm) -8.7
Return on Equity (ttm) -25.7
Qtrly Rev. Growth 12.3
Gross Profit (p.s.) 1.38
Sales Per Share 3.74
EBITDA (p.s.) -0.37
Qtrly Earnings Growth 0
Operating Cash Flow 2 (M)
Levered Free Cash Flow 3 (M)

Stock Valuations

PE Ratio -2.01
PEG Ratio -0.1
Price to Book value 0.47
Price to Sales 0.28
Price to Cash Flow 9.3

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-09-07
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.